Analysts Set Exagen Inc. (NASDAQ:XGN) Price Target at $12.00

Shares of Exagen Inc. (NASDAQ:XGN) have received a consensus rating of “Moderate Buy” from the nine brokerages that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating and eight have issued a buy rating on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $12.00.

A number of analysts recently weighed in on XGN shares. Weiss Ratings restated a “sell (d-)” rating on shares of Exagen in a report on Wednesday, October 8th. B. Riley initiated coverage on shares of Exagen in a research note on Thursday, September 11th. They issued a “buy” rating and a $15.00 price objective for the company. Canaccord Genuity Group raised their price objective on shares of Exagen from $8.00 to $11.00 and gave the stock a “buy” rating in a research note on Wednesday, July 30th. KeyCorp raised shares of Exagen from a “sector weight” rating to an “overweight” rating and set a $12.00 price objective for the company in a research note on Wednesday, July 30th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $10.00 price objective on shares of Exagen in a research note on Wednesday, July 30th.

Exagen Trading Down 1.2%

Shares of NASDAQ:XGN opened at $10.95 on Monday. The stock has a market capitalization of $240.90 million, a price-to-earnings ratio of -12.30 and a beta of 1.54. Exagen has a 1-year low of $2.38 and a 1-year high of $11.27. The company has a debt-to-equity ratio of 1.06, a quick ratio of 4.95 and a current ratio of 4.95. The company has a 50 day moving average price of $9.93 and a 200 day moving average price of $7.57.

Exagen (NASDAQ:XGN) last issued its earnings results on Tuesday, July 29th. The company reported ($0.18) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.18). The firm had revenue of $17.20 million during the quarter, compared to analysts’ expectations of $16.25 million. Exagen had a negative net margin of 28.85% and a negative return on equity of 130.38%. Exagen has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Exagen will post -0.88 EPS for the current fiscal year.

Hedge Funds Weigh In On Exagen

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Palumbo Wealth Management LLC boosted its stake in Exagen by 14.4% in the 1st quarter. Palumbo Wealth Management LLC now owns 99,205 shares of the company’s stock worth $356,000 after purchasing an additional 12,501 shares during the period. Huntleigh Advisors Inc. boosted its stake in shares of Exagen by 16.8% during the 1st quarter. Huntleigh Advisors Inc. now owns 83,108 shares of the company’s stock valued at $298,000 after buying an additional 11,939 shares during the period. Ameriprise Financial Inc. acquired a new stake in shares of Exagen during the 2nd quarter valued at $663,000. Bridgeway Capital Management LLC boosted its stake in shares of Exagen by 10.3% during the 2nd quarter. Bridgeway Capital Management LLC now owns 27,800 shares of the company’s stock valued at $194,000 after buying an additional 2,600 shares during the period. Finally, Occudo Quantitative Strategies LP acquired a new stake in shares of Exagen during the 2nd quarter valued at $138,000. Institutional investors and hedge funds own 75.25% of the company’s stock.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).